We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+4.41%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$279M
AUM Growth
-$62.9M
(-18%)
Cap. Flow
-$59.8M
Cap. Flow
% of AUM
-21.41%
Top 10 Holdings %
Top 10 Hldgs %
47.37%
Holding
72
New
12
Increased
18
Reduced
11
Closed
26
Top Buys
| 1 |
Ascendis Pharma A/S
ASND
|
+$10.4M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$8.55M |
| 3 |
MRUS
Merus
MRUS
|
+$7.77M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$5.58M |
| 5 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$5.02M |
Top Sells
| 1 |
Xenon Pharmaceuticals
XENE
|
+$20.6M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$15.4M |
| 3 |
ALLK
Allakos
ALLK
|
+$9M |
| 4 |
GH Research
GHRS
|
+$6.59M |
| 5 |
Aldeyra Therapeutics
ALDX
|
+$5.34M |
Sector Composition
| 1 | Healthcare | 92.01% |
| 2 | Financials | 1.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CYPH
26
Cypherpunk Technologies Inc
CYPH
$75.4M
| $4.37M | 1.57% |
135,000
-30,000
| -18% | -$833K |
|
|
KZR
27
DELISTED
Kezar Life Sciences
KZR
| $4.18M | 1.5% |
+25,000
| New | +$2.82M |
|
|
STSA
28
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $4.07M | 1.46% |
904,225
| – | – |
|
29
VistaGen Therapeutics
VTGN
$9.4M
| $3.9M | 1.4% |
66,667
| – | – |
|
30
Tarsus Pharmaceuticals
TARS
$2.61B
| $3.83M | 1.37% |
170,000
| – | – |
|
|
BLU
31
DELISTED
BELLUS Health Inc.
BLU
| $3.62M | 1.3% |
450,000
+50,000
| +13% | +$332K |
|
32
Crinetics Pharmaceuticals
CRNX
$8.88B
| $3.36M | 1.2% |
118,344
-31,656
| -21% | -$780K |
|
33
Pyxis Oncology
PYXS
$150M
| $3.24M | 1.16% |
+295,000
| New | +$3.38M |
|
|
NMTR
34
DELISTED
9 Meters Biopharma
NMTR
| $3.18M | 1.14% |
162,500
+25,000
| +18% | +$559K |
|
35
Kura Oncology
KURA
$964M
| $3.15M | 1.13% |
225,000
-200,000
| -47% | -$3.24M |
|
|
36
Xenon Pharmaceuticals
XENE
$6.6B
| $3.12M | 1.12% |
100,000
-690,000
| -87% | -$20.6M |
|
|
CTIC
37
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $2.98M | 1.07% |
1,200,000
-400,000
| -25% | -$979K |
|
38
Design Therapeutics
DSGN
$785M
| $2.89M | 1.04% |
+135,000
| New | +$2.32M |
|
39
Larimar Therapeutics
LRMR
$384M
| $2.43M | 0.87% |
225,000
+25,000
| +13% | +$278K |
|
|
40
GH Research
GHRS
$1.97B
| $2.33M | 0.84% |
100,000
-300,000
| -75% | -$6.59M |
|
|
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.76M | 0.63% |
+60,000
| New | +$1.86M |
|
42
Immunic
IMUX
$207M
| $1.58M | 0.57% |
16,500
-10,000
| -38% | -$901K |
|
|
RETA
43
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.45M | 0.52% |
+55,000
| New | +$4.26M |
|
|
44
CALL
Aldeyra Therapeutics
ALDX
$102M
| $1.2M | 0.43% |
+300,000
| New | +$2.29M |
|
|
PRDS
45
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $819K | 0.29% |
+50,000
| New | +$582K |
|
46
Cabaletta Bio
CABA
$461M
| $512K | 0.18% |
135,000
+35,000
| +35% | +$373K |
|
|
47
Aldeyra Therapeutics
ALDX
$102M
| – | – |
-700,000
| Closed | -$5.34M |
|
48
Alector
ALEC
$167M
| – | – |
-80,000
| Closed | -$1.83M |
|
|
ALLK
49
DELISTED
Allakos
ALLK
| – | – |
-85,000
| Closed | -$9M |
|
50
Allogene Therapeutics
ALLO
$618M
| – | – |
-150,000
| Closed | -$3.85M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q4 2021 Portfolio in Review
As of Q4 2021, Ghost Tree Capital held 72 positions worth $279M, down 18% from $342M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Ghost Tree Capital withdrew a net $59.8M in Q4 2021, closing 26 positions and reducing 11 holdings. Its most notable exit was Iovance Biotherapeutics, an estimated $15.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials.
Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $9.01M.
- Ghost Tree Capital's largest Q4 2021 buy was Sarepta Therapeutics: 100,000 shares worth $9.01M.
- Ghost Tree Capital added most to Ascendis Pharma A/S in Q4 2021, an estimated $10.4M increase.
- Ghost Tree Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $20.6M.
- Ghost Tree Capital fully exited Iovance Biotherapeutics in Q4 2021, selling an estimated $15.4M.
- Ghost Tree Capital's ten largest holdings make up 47% of its $279M portfolio in Q4 2021.
- Ghost Tree Capital opened 12 new positions and closed 26 in Q4 2021.
- Ghost Tree Capital's portfolio value fell 18% quarter-over-quarter to $279M.
Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.